載入中
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
前收盤價
US$1.45
−US$0.07 · -4.61%
盤中時間採用ET。市場資料可能有所延遲。
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
日內區間
目前US$1.45
52週區間
目前US$1.45
盤中時間採用ET。市場資料可能有所延遲。
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
日內區間
目前US$1.45
52週區間
目前US$1.45
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 20.09萬 USD | 33.75萬 USD | 40.8萬 USD | 43.52萬 USD | 68.16萬 USD |
| 毛利 | −20.09萬 USD | −33.75萬 USD | −40.8萬 USD | −43.52萬 USD | −68.16萬 USD |
| 研究與開發 | 278.1萬 USD | 284.13萬 USD | 725.24萬 USD | 802.78萬 USD | 478.88萬 USD |
| 銷售、一般及管理費用 | 579.26萬 USD | 645.35萬 USD | 878.8萬 USD | 1149.85萬 USD | 2047.41萬 USD |
| 營業費用 | 857.36萬 USD | 929.48萬 USD | 1604.04萬 USD | 1952.62萬 USD | 2526.29萬 USD |
| 利息收入 | — | 219 USD | — | 5.25 USD | 10.32 USD |
| 利息支出 | 106 USD | — | 3708 USD | 5249 USD | 1.03萬 USD |
| 折舊和攤銷 | 20.09萬 USD | 33.75萬 USD | 40.8萬 USD | 43.52萬 USD | 68.16萬 USD |
| 營業利益 | −877.44萬 USD | −963.23萬 USD | −1644.84萬 USD | −1996.14萬 USD | −2594.45萬 USD |
| 淨利 | −1213.15萬 USD | −957.5萬 USD | −1.73萬 USD | −1850.43萬 USD | −4897.69萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2008年4月23日 | US$0.021Irregular | 2008年4月15日 | — |
除息 2008年4月23日
US$0.021
Irregular
2008年4月15日登記
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
